SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONCOCYTE :Liquid Biopsy
OCX 6.630+6.6%Oct 24 3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant12/7/2016 10:17:48 AM
   of 29
 
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at VirtualInvestorConferences.com on Wednesday, December 14, 2016 at 1:00 p.m. Eastern Time (ET).

For investors who are not yet familiar with the Company, an informational video and investor presentation is available on Organovo's website: organovo.com

Date: Wednesday, December 14, 2016

Time: 1:00 p.m. ET/10:00 a.m. PT

Link: tinyurl.com

It is recommended that investors pre-register to save time and receive event updates. This will be a live, interactive online event where investors are invited to ask the company questions in real-time, both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Learn more about the event at www.VirtualInvestorConferences.com.

About Organovo Holdings Inc.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company's ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Logo - photos.prnewswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/organovo-to-present-on-december-14-in-a-live-interactive-webcast-at-virtualinvestorconferencescom-300374333.html

SOURCE Organovo Holdings, Inc.

/CONTACT: Investor Contact: Steve Kunszabo, Organovo Holdings, Inc., +1 (858) 224-1092, skunszabo@organovo.com; Press Contact: Jessica Yingling, Little Dog Communications, +1 (858) 480-2411, jessica@litldog.com

/Web site: organovo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext